CC
SUPN icon

Centiva Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Centiva Capital’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,108
Closed -$331K – 2025
2025
Q1 		$331K Buy
10,108
+957
+10% +$33.9K 0.01% 1029
2024
Q4 		$331K Buy
+9,151
New +$322K 0.01% 1070
2024
Q3 		– Sell
-11,719
Closed -$313K – 2582
2024
Q2 		$313K Buy
+11,719
New +$340K 0.01% 1432
2024
Q1 		– Sell
-8,538
Closed -$247K – 2237
2023
Q4 		$247K Buy
+8,538
New +$226K 0.01% 1310
2023
Q2 		– Sell
-6,977
Closed -$253K – 1979
2023
Q1 		$253K Buy
+6,977
New +$268K 0.01% 1133
2020
Q2 		– Sell
-11,485
Closed -$207K – 805
2020
Q1 		$207K Buy
+11,485
New +$241K 0.01% 440

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Centiva Capital's SUPN Position: Q2 2025 in Review

Centiva Capital sold out of Supernus Pharmaceuticals (SUPN) in Q2 2025, closing a stake of 10,108 shares — an estimated $331K sold.

Centiva Capital first reported a position in SUPN in Q1 2020 and held it in 6 quarters. The position peaked at $331K in Q1 2025. 295 funds tracked by Wall St. Rank hold SUPN as of Q2 2025.

  • Centiva Capital reported no remaining Supernus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Centiva Capital sold 10,108 Supernus Pharmaceuticals shares in Q2 2025, an estimated $331K.
  • Centiva Capital first reported a position in Supernus Pharmaceuticals in Q1 2020 and held it in 6 quarters.
  • Centiva Capital's Supernus Pharmaceuticals position peaked at $331K in Q1 2025.
  • 295 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2025.

Based on Centiva Capital's 13F filing for Q2 2025, filed 13 Aug 2025.